Pure Global
NCT06372223

A Food Effect Study of SPH5030 Tablets.

A Single-center, Randomized, Open, Single-dose, Two-cycle, Two-sequence Crossover Food Effect Study of SPH5030 Tablets in Healthy Chinese Adult Subjects.
Shanghai Pharmaceuticals Holding Co., Ltd·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
SPH5030
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Location
Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 04, 2024
End date
Mar 25, 2024
Enrollment
16 participants
Primary outcome

Peak Plasma Concentration (Cmax),Peak time（Tmax）,Area under the plasma concentration versus time curve (AUC)

Summary

The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy
 Chinese adult subjects.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06372223
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06372223 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and is currently Completed. The study focuses on Advanced Solid Tumor. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.